Fabrication via a nonaqueous nanoprecipitation method, characterization and in vitro biological behavior of N6-cyclopentyladenosine-loaded nanoparticles

Journal of Pharmaceutical Sciences

Volumn 98, Issue 11, 2009, Pages 4272-4284

  Dalpiaz, Alessandro ^a   Vighi, Eleonora ^b   Pavan, Barbara ^a   Leo, Eliana ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Human retinal pigment epithelium cells; Kinetics; Membrane transporter; Nanoparticles N 6 cyclopentyladenosine; Poly(lactic glycolic) acid (PLGA, PLA); Polymeric drug delivery systems; Stability

Indexed keywords

6 N CYCLOPENTYLADENOSINE; COTTON SEED OIL; NANOPARTICLE; NUCLEOSIDE TRANSPORTER; POLYSORBATE 80;

ANALYTIC METHOD; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD; CELL LEVEL; CONTROLLED STUDY; DEGRADATION KINETICS; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE PERMEABILITY; MORPHOLOGY; NONAQUEOUS NANOPRECIPITATION METHOD; PARTICLE SIZE; PIGMENT EPITHELIUM;

EID: 70349644433     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21710     Document Type: Article

References (37)

1. Dalpiaz A, Manfredini S. 2002. Adenosine A1 receptor: Analysis of the potential therapeutic effects obtained by its activation in the central nervous system. Curr Med Chem 9:1923-1927. (Pubitemid 35230259)
2. Jacobson KA, Trivedi BK, Churchill PC, Williams M. 1991. Novel therapeutics acting via purinergic receptors. Biochem Pharmacol 41:1399-1410.
3. Heurteaux C, Lauritzen I, Widmann C, Lazdunski M. 1995. Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive Kchannels in cerebral ischemic preconditioning. Proc Natl Acad Sci USA 92:4666-4670.
4. Tucker L, Linde J. 1993. Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res 27:62-67. (Pubitemid 23035667)
5. Brodie MS, Lee K, Fredholm BB, Stahle L, Dunwiddie TV. 1987. Central versus peripheral mediation of responses to receptor agonists: Evidence against a central mode of action. Brain Res 415:323-330. (Pubitemid 17100338)
6. 1 receptor agonists in situ: Role of the rENT1 nucleoside transporter and binding to blood constituents. Eur J Pharm Sci 24:59-66.
7. Dalpiaz A, Gavini E, Colombo G, Russo P, Bortolotti F, Ferraro L, Tanganelli S, Scatturin A, Menegatti E, Giunchedi P. 2008. Brain uptake of an antiischemic agent by nasal administration of microparticles. J Pharm Sci 97:4889-4903.
8. 1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. J Chromatogr 620:113-120.
9. Dalpiaz A, Contado C, Vighi E, Tosi G, Leo E. 2008. Preparation and characterization of particulate drug delivery systems for the brain targeting. In: Ravi Kumar MNV, editor. Handbook of particulate drug delivery, Vol.2. Stevenson Ranch, CA, USA: American Scientific Publishers. pp. 1-25.
10. Dalpiaz A, Leo E, Vitali F, Pavan B, Scatturin A, Bortolotti F, Manfredini S, Durini E, Forni F, Brina B, Vandelli MA. 2005. Development and characterization of biodegradable nanoparticles as delivery systems of antiischemic adenosine derivatives. Biomaterials 26:1299-1306. (Pubitemid 39314504)
11. Leo E, Contado C, Bortolotti F, Pavan B, Scatturin A, Tosi G, Manfredini S, Angusti A, Dalpiaz A. 2006. Nanoparticle formulation may affect the stabilization of an antiischemic prodrug. Int J Pharm 307:103-113. (Pubitemid 41773258)
12. Leo E, Scatturin A, Vighi E, Dalpiaz A. 2006. Polymeric nanoparticles as drug controlled release systems: A new formulation strategy for drugs with small or large molecular weight. J Nanosci Nanotech 6:3070-3079. (Pubitemid 44579984)
13. 1 receptor agonist. Pharm Res 18:531-536.
14. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. 1989. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1-R4. (Pubitemid 19247505)
15. Toimela T, Mäenpää H, Mannerström M, Tä hti H. 2004. Development of an in vitro blood-brain barrier model - Cytotoxicity of mercury and aluminium. Toxicol Appl Pharmacol 195:73-82.
16. Pavan B, IJzerman AP. 1998. Processing of adenosine receptor agonists in rat and human whole blood. Biochem Pharmacol 56:1625-1632. (Pubitemid 28561482)
17. Jennings LL, Hao C, Cabrita MA, Vickers MF, Baldwin SA, Young JD, Cass CE. 2001. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology 40:722-731. (Pubitemid 32323996)
18. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. 1999. PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J Control Release 57:171-185. (Pubitemid 29062869)
19. Bouchemal K, Briançon S, Perrier E, Fessi H. 2004. Nano-emulsion formulation using spontaneous emulsification: Solvent, oil and surfactant optimization. Int J Pharm 280:241-251. (Pubitemid 38960674)
20. Bilati U, Allemann E, Doelker E. 2005. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci 24:67-75. (Pubitemid 40051288)
21. Gaumet M, Vargas A, Gurny R, Delie F. 2008. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur J Pharm Biopharm 6:1-9.
22. Kreuter J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65-81. (Pubitemid 32209233)
23. Petri B, Bootz A, Khalansky A, Hekmatara T, Mueller R, Uhl R, Kreuter J, Gelperina S. 2007. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. J Control Release 117:51-58. (Pubitemid 46164866)
24. Barnabas W, Malay KS, Kumaraswamy S, Kokilampal Perumal SK, Nallupillai P, Bhojraj S. 2008. Poly(n-butyl cyanoacrylate) nanoparticles coated with Polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 1200:159-168.
25. 1 receptor agonist. J Control Release 73:303-313.
26. Dalpiaz A, Mezzena M, Scatturin A, Scalia S. 2008. Solid lipid microparticles for the stability enhancement of the polar drug N(6)-cyclopentyladenosine. Int J Pharm 355:81-86.
27. Lee G, Dallas S, Hong M, Bendayan R. 2001. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 53:569-596. (Pubitemid 33136238)
28. Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A, Kwong FY, Coe I, Cass CE, Young JD, Baldwin SA. 1997. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3:25-26. (Pubitemid 27019148)
29. Griffiths M, Yao SY, Abidi F, Phillips SE, Cass CE, Young JD, Baldwin SA. 1997. Molecular cloning and characterization of a nitrobenzylthioinosine- insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 328:739-743. (Pubitemid 28005769)
30. Ritzel MW, Yao SY, Ng AM, Mackey JR, Cass CE, Young JD. 1998. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 15:203-211.
31. Ritzel MW, Yao SY, Huang MY, Elliott JF, Cass CE, Young JD. 1997. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am J Physiol 272:C707-C714.
32. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides. J Biol Chem 276:2914-2927.
33. Baldwin SA, Yao SY, Hyde RJ, Ng AM, Foppolo S, Barnes K, Ritzel MW, Cass CE, Young JD. 2005. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 280:15880-15887. (Pubitemid 40616710)
34. King AE, Ackley MA, Cass CE, Young JD, Baldwin SA. 2006. Nucleoside transporters: From scavengers to novel therapeutic targets. Trends Pharmacol Sci 27:416-425. (Pubitemid 44051567)
35. Schaddelee MP, Voorwinden HL, van Tilburg EW, Paterman TJ, Ijzerman AP, Danhof M, de Boer AG. 2003. Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: Possible implications for the design of synthetic adenosine derivatives. Eur J Pharm Sci 19:13-22. (Pubitemid 36506933)
36. 1 receptor agonists in vitro: Structure transport relationships. Eur J Pharm Sci 20:347-356.
37. Sun W, Xie C, Wang H, Hu Y. 2004. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 25:3065-3071. (Pubitemid 38210199)